CAR-T Cell Products Pipeline
The CAR-T-19 series forms the core of our CAR-T cell product pipeline. Our CAR-T-19 injection product candidate has shown efficacy in a clinical study, and our IND application for the product candidate with B-cell acute lymphoblastic leukaemia (B-ALL) as the clinical indication was accepted for processing by the CDE in August
2019. Based on the technology of the CAR-T-19 injection, our CAR-T-19-DNR injection and aT19 injection product candidates have the ultimate goal of overcoming CAR-T cells’ pain points in terms of the lack of persistence, the lack of efficacy in the treatment of solid tumours, and in the prevention of tumour recurrence. If verified, the technology underlying these two product candidates may be used in the genetic modification of other CAR-T and TCR-T cell products targeting solid tumours.
Corresponding parameter set not found, please add it in property template of background